Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Dis Markers. 2010;28(4):209-24. doi: 10.3233/DMA-2010-0707.
Our understanding of human disease and potential therapeutics is improving rapidly. In order to take advantage of these developments it is important to be able to identify disease markers. Many new high-throughput genomics and proteomics technologies are being implemented to identify candidate disease markers. These technologies include protein microarrays, next-generation DNA sequencing and mass spectrometry platforms. Such methods are particularly important for elucidating the repertoire of molecular markers in the genome, transcriptome, proteome and metabolome of patients with diseases such as cancer, autoimmune diseases, and viral infections, resulting from the disruption of many biological pathways. These new technologies have identified many potential disease markers. These markers are expected to be valuable to achieve the promise of truly personalized medicine.
我们对人类疾病和潜在疗法的理解正在迅速提高。为了利用这些发展，识别疾病标志物非常重要。许多新的高通量基因组学和蛋白质组学技术正在被用于识别候选疾病标志物。这些技术包括蛋白质微阵列、下一代 DNA 测序和质谱平台。这些方法对于阐明患有癌症、自身免疫性疾病和病毒感染等疾病的患者的基因组、转录组、蛋白质组和代谢组中的分子标志物谱特别重要，这是由于许多生物途径的破坏。这些新技术已经鉴定出许多潜在的疾病标志物。这些标志物有望实现真正个性化医疗的承诺。
